GLP1 agonist drugs, commonly known by brand names such as Ozempic and Mounjaro, reduce asthma symptoms in obese people according to a study from the University of Aberdeen and The Observational and Pragmatic Research Institute (OPRI), Singapore.
An international team of scientists led by University of Aberdeen Chair in Primary Care Respiratory Medicine, Professor David Price, analysed the medical records of more than 60,000 patients. Using the OPCRD database – a primary care patient database containing over 28 million patients, they compared measures of asthma severity between those who had been prescribed GLP1s and those who hadn’t over an entire year.
They found that as well as the expected weight loss in people who were taking GLP1s, the asthma measures such as steroid and medication prescriptions, were also reduced.
View: https://link.springer.com/article/10.1007/s12325-025-03175-x
